Media Highlights

Media Highlights

CAR T-Cell Therapy Safe, Feasible for Patients With Lymphoma in Complete Remission Before Cell Therapy Begins

December 13, 2023

Data presented by Sylvester Comprehensive Cancer Center researchers, Trent Wang, DO, MPH and Antonio M. Jimenez Jimenez, MD, MSc, at the 2023 ASH Annual Meeting & Exposition suggest that chimeric antigen receptor (CAR) T-cell immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.

Read the Full article

Tags:   Sylvester Comprehensive Cancer Center